MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. announced that the Phase II clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.